Clinical trials: CTLA4
Resectable Hepatocellular Carcinoma
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
- Trial name
- NCT07714317
- Testing
- IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital